Again, it's the only PI3K inhibitor which readily crosses the BBB.
Many drugs cross the BBB. And some of those that don't can be formulated as a nasal spray which bypasses the BBB.
As far as cancer therapies that can cross the BBB go, off the top of my head:
Temozolomide, the only current FDA-approved drug for GBM, readily crosses the BBB.
Kintara Therapeutics' VAL-083, the other drug currently in the GBM AGILE study, readily crosses the BBB. Their drug looks very promising, just like Pax.
Both PAT-DX1 and PAT-DX3 being developed by Patrys (ASX : PAB) readily cross the BBB. They are also considering the possibilities of using those assets to transport other drugs across the BBB.
Still, PI3K is a highly validated target and the fact that KZA has the only PI3K inhibitor which crosses the BBB is exciting.
- Forums
- ASX - By Stock
- KZA
- How does GBM AGILE work?
How does GBM AGILE work?, page-11
-
- There are more pages in this discussion • 63 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KZA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online